Limitations of currently available Chagas disease chemotherapy.

1 Rev Esp Quimioter 2012;25 (1):1-3 post-treatment, which was deemed to reflect the effectiveness of the treatment to clear parasites better than serology. Moreover, PCR allowed treatment failure to be ratified – in our case in 6.9% of the patients, who shifted to positive at the end of the follow-up period. Although PCR is a sensitive and specific tool for the early detection of the parasite’s susceptibility to treatment, a negative PCR result does not necessarily indicate parasitological cure of the patients in the absence of other markers.

[1]  Pedro Albajar Viñas,et al.  Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients. , 2012, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[2]  M. Segovia,et al.  Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. , 2011, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[3]  M. Segovia,et al.  Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country. , 2010, The Journal of antimicrobial chemotherapy.

[4]  C. Bern,et al.  Chagas disease in Spain, the United States and other non-endemic countries. , 2010, Acta tropica.

[5]  R. López-Vélez,et al.  Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. , 2009, The Journal of antimicrobial chemotherapy.

[6]  Z. Cucunubá,et al.  Characterising the KMP-11 and HSP-70 recombinant antigens' humoral immune response profile in chagasic patients , 2009, BMC infectious diseases.

[7]  M. Segovia,et al.  [Congenital Chagas disease in a newborn of a Bolivian mother]. , 2009, Enfermedades infecciosas y microbiologia clinica.

[8]  J. Coura Present situation and new strategies for Chagas disease chemotherapy: a proposal. , 2009, Memorias do Instituto Oswaldo Cruz.

[9]  J. Urbina,et al.  Ergosterol biosynthesis and drug development for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[10]  J. Urbina,et al.  Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. , 2008, Bioorganic & medicinal chemistry.

[11]  J. Muñoz,et al.  Congenital Trypanosoma cruzi infection in a non-endemic area. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  P. Hotez,et al.  Control of neglected tropical diseases. , 2007, The New England journal of medicine.

[13]  J. Altcheh,et al.  Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. , 2003, The Journal of antimicrobial chemotherapy.

[14]  E. Segura,et al.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.

[15]  Simonne Almeida e Silva,et al.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection , 1996, The Lancet.